CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
· seekingalpha.com
CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing is one of the most important advances in modern biotechnology, allowing scientis...